US00534A1025 - Common Stock
INVIVYD INC
NASDAQ:IVVD (5/9/2024, 7:00:02 PM)
After market: 2.36 -0.06 (-2.48%)2.42
-0.11 (-4.35%)
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2021-08-06. The company is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases. The company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify antibodies with a barrier to viral escape. The company has a robust pipeline of antibody candidates for the prevention and treatment of COVID-19, including VYD222, a novel antibody. VYD222 is a monoclonal antibody candidate that has demonstrated in vitro neutralizing activity against dominant variants of concern, including XBB.1.5. VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.
INVIVYD INC
1601 Trapelo Road, Suite 178
Waltham MASSACHUSETTS
P: 17818190080
Employees: 84
Website: https://invivyd.com/
IVVD stock results show that Invivyd met analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Invivyd (NASDAQ:IVVD) just reported results for the first quarter of 2024.Inviv...
Launched PEMGARDAâ„¢ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune...
Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial...
Here you can normally see the latest stock twits on IVVD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: